BIO CEO & Investor Conference
Monday, February 12, 2018 • 3:15 p.m. ET
New York, NY
Armis Biopharma is a late-stage clinical biopharmaceutical company with a growing pipeline of targeted anti-infective therapeutics designed to address antibiotic resistance and healthcare-associated infections, a serious and rapidly growing phenomenon.
The Company’s lead product candidate, Ximycin™, is a patented, first-of-its-kind localized antimicrobial therapy derived from a combination of a gram-positive agent, vancomycin, and a gram-negative agent, gentamicin, two potent well-established and accepted agents. Ximycin™ utilizes a proprietary sustained-release delivery method via gel formulation, enabling temporally-extended, broad spectrum polymicrobial coverage in the incision site. Ximycin is initially being developed for use as a prophylactic therapy for the mitigation or prevention of multi-drug resistant surgical site infections (“SSIs”), including multi-drug resistant gram-negative and/or gram-positive infections.
Armis is also focused on developing and commercializing a proprietary, first-of-its-kind, peracid-based anti-infective technology and acquiring other synergistic technologies/products.
Our mission is to decrease the quantity and severity of infections that cause human suffering and death through the creation and development of novel, targeted antimicrobial therapies designed to achieve:
We are focused on targeted/localized antimicrobial agents that may work in tandem with systemic antimicrobial agents or could be used as monotherapies to provide better patient outcomes. A key part of our strategy is to in-license/acquire systemic antimicrobial therapies that fit our commercial objectives.